%%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝...

15
. ) ( : # $ %% &’ ( : / / *+ &’ : ,- / / ! "#$ % * : ! "#$% ) ’#()*+ ,$ )$-. ( 0 1) 2 3 )4 "#)%5 5 ’536 75 $.7 8 ), + 9:; ’( <=> % . ’8@ "# 9:; ( AB " C! ! D ( "#$% <E, D! 3 "#)% ’36 F$: G . 1) 2 3 $5 5# G5 . 5 , . : AB " ) D!, D3 JK G . F$: 1) 2 ) 5( "#L# JM / O ± OQ / RR 3 )5; 5 M2 / J ± 2J / JR ( ’.7 S . T, !, 37 JK . G $ # ) ( "#L# J / M ± R / RJ )5; 3 QU / R ± KR / JK ( ) . 5V+ W3 5 5#*# T5.3X 5, D5#7 5 . ’5#- NycoCard D5#7 5 D5 @)Y#@7 "#)@7)! ) HbA1c ( 7 Z$( . ( [)B( "#$% V-)@7 3 "#)% \#;; ()) D! W3 #%- V-)@7 3 V+ , D#7 . 36 <E, ]). Z$( "#)% ) HOMA-IR ( 7 :( . : ( [)B( V-)@7 3 @)Y#@7 "#)@7)! ^ _#)$( )E>. %#@7 D; $, ’36 <E, "#)% ) HOMA-IR ( . ) )B F- $># D A . !, ) . ( [)B( "#L# CF$E "#$% "# 3 37 + 8 A D ): 37 3 ! D A F- )B 5 $>5# )5 ) RQ / R ± K / a T6 J / 2 ± MU / K 37 $ # ( 3 ) Ma / J ± RO / U T6 Ma / J ± K / K $ 37 ( . "# D A L$%:! , D#7 D!#b$ "#$% ( [)B( ! SYc# 3 L !> 37 . 3 5Z L$%:! 5A D 3 "#$% "# !> !, 37 06. _#)$( )E>. 7 . : CF$E "#$% ( [)B( G . 1) F$: 2 3 $5 # G . 5A )5: 3 5#A $% ’( d 0 "# 3 % , ! . : 1) 2 "#)% ’36 <E, "#$% ) HOMA-IR ( ); 1 - 6#6; V- 3 eb; S)@d 3 D- V:; Y,VX S)@d L> 2 f 3 6#6; V- 3 V g; Y,VX S)@d L> h%#)$ * ./0/ : !"#$ %& : [email protected]

Upload: others

Post on 25-Jan-2020

8 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

����� ���� �� �� ���� .��� �������� ��)�� � �(:�#$%%

&�� '�( ��� :��/�/��

*��+� &�� ' :,-/�/��

و ارتباط سطح سرمي رزيستين با شاخص هاي مقاومت به انسولين در افراد چاق ديابتي غير ديابتي

�������� �� ������� � ��� � ��*��������� ����

چكيده ��:مقدمه!"#$%���)'#()*��+ �� ��, $� �)$-�.(�� ��� 0��� 1)� '����23)4 �� "#�)%5�� �5� '5�3�6� �� �7�5�

�� �$. 7 8� �),�'���� �� + 9�:;�� �����'(� ����� ���� <=>��� �%��.'8@� "#� 9�:;�� �(� � �A��B� "�� C�! �!D

� (��� "#$%��� <E�, D�! 3 "#�)%�� �� '�3�6� � �� F$:� G� �� .� �� ��� 1)� '���23�$��5�� 5#� G�5 �� .� �5�

�,��.

�� ��" �B��A:ها روش)� �–D�!�, D3� JKG� � . F$:� ��1)� '���� 2)��5( "#L��#� ��JM/O±OQ/RR3��)5; �5����

����M2/J±2J/JR('. 7 S���� .T��, �!�, �3 7JK� . G� �$���� #� )��( "#L��#� ���J/M±�R/RJ��)5; ����� 3

����QU/R±KR/JK(�)� .�5��V�+ W3� �5� �5#*#� T5��.3 X �5, D 5#7 ����5�� .'5#- �� NycoCard D 5#7 ����5�� D� 5�

�@��)Y#@7 "#�)@7)�!)HbA1c ( ��� 7 ���Z$(� .�� ( [)B( "#$%��� V-)@7 3 "#�)%��� ��\#; ; �(�)�)��� D�! W3� ��

���#%-� V-)@7 3 ���V�+ ������ ���, D #7 .3�6� <E�,�])� . �� ���Z$(� �� "#�)%�� �� ')HOMA-IR ( ��� 7 �:(���.

��:ها يافته( [)B( V-)@7 3 �@��)Y#@7 "#�)@7)�! �^�� � _#�)$(��� )E��>.� �� %#@7 D ; ��$,�� �� '�3�6� <E�,

"#�)%��)HOMA-IR ( �� .��� ��)��)B� F̀��- �� $>#� D��� ��A� �� .��!�, �)� .�� ( [)B( "#L��#� CF$E� "#$%���

� "#�3�3 7 ���+ 8� �� ��A� D��� �):� ������3 7 3� !�� D��� ��A� F��- �)B� �� 5� �� $>5#� ��� �)5�)RQ/R±�K/a

T��6� ��J�/2±MU/K�3 7 �� �$���� #� (3)Ma/J±RO/UT��6��� Ma/J±K�/K�$���� �3 7�� (."#� D��� ��A� �L$%:�!

�� ��, D #7 ������ D�! #b$� �� "#$%��� �� ( [)B(!�� S��Yc# 3���� L� ��!�>� �3 7 .3 �5Z�� �L$%:�! �5�A� D���

3 "#$%��� "#� �!�>� �!�, �3 7 �� 06. _#�)$(��� )E��>.��� 7 �.

���%$#" �CF$E: گيري نتيجه �� ( [)B( G� �� .� 1)� '���� �� F$:� 23$��5�� #� G� �� .���5�A� ����)5:�3�5#A�

$%��� '(� ���d 0��� "#3 ��� �� '���� �%�� �,�� �!.

�� ��%(�#"2 ���� ����' �(1: واژگان كليدي '�3�6� <E�,� "#$%���� )HOMA-IR ( �� ��); ������

1-��6#6�; V- � 3 ��eb; S)@d ��3��� D� ���-�V� :; �Y,VX S)@d ��L>���

2f3�� ��� ��6#6�; V- � 3 V�� � g; �Y,VX S)@d ��L>��� �h%#�)��$�

*./ 0/ : ������ ��� � ��������� ����������� ����� ���� ����� !��"�#�$� %&� :[email protected]

Page 2: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

��� 1�2 .� 3�4 :5 2 67 � 8�9:�;� .��< =>< ? @'��... %�

مقدمه��3 �� 3 ��� 1)5� '����2�5g4 ���5#X� ��5,�� �5� ��.

��� ��T��)d BE ��( 1)� '���� C3 A�2�5,�� ��3

�̀���, %�� �� '�3�6� �� ���� 9�:;�� "#�).���5 "#5�c�!

55�3�6� i��V55.� �55� 3 "#�)%55�� �55� ''558@� i��V55.�

V-)@7)E�1)� '���� ] $�- 2 ; ��#c#X �� �5�- �5�]�[.

� '�3�6��"#�)%�� �� �,�� �� "#�)%5�� S�#X ]�6$�� ]F$E�

'.�� �!DC�! V#� 3 ])5�A� '5@d 1)5� '5���� j5���2

�� �,�� .'.�� �� ��#�); k� l 3 �m, ; h8���� D���A;

��;3 X#"#�!���@�4 �)$-�. �3 Y� �5Z�+ ���!�)TNF-α(�

����- ��g��fn)�#�(FX ����- ]�A. )PAI-1 ( �� "#5$*�

"#$Y�)55*��+"#%55��;)�o�+ �3"#$%55��� �55� '55�3�6� ��

"#�)%�� ���� ��g� i6� ]pf�[."#$%��� �5��4 )��)!

� ��55, $��'#55()*��+ 3 �55! ���)��55E �55� k55@A$� �� D�

;3 X#"#�!D#( �� ��� T#%-)� - D�g$�� �� %�� "#q$ �5,��

�55� �5-RELM)"#$%55��� ���>5� �55! ])5Y�)� (�55�FIZZ

)�)4)��)$-�. �#r����(V#� '5(� C3 5A� ]�sft[."5��

!�)��55$�� )55� ��)�55� mRNA3 �55�� 7 ��554 u*55(

��� 7 <=>� 0(); + �#� �-+'%5#�)7 D�5! PPARγ

�� v)- ( �),.��5A��B�D3� ]�5� �� ���5! �� '5����

"#�)%5�� �� '#(�%r T��)d "�� �- ��� - '��w �7��)4

�� i��V.� �� ��!� ]a[��g�>5#X x�5(� "�� � �5�� 7 �5-

"#$%55��� ���� �::55( i556� "#�)%55�� �55� '55�3�6� ��

]a������[.�� ! �%5�� D3� ��5A$� ��A��B� �>5� �5!

����� � �� �- �� "#$%5��� y�5�� �#� T#� '#5()*��+ D�5!

��%����i6� +�)�d ��T��d �� ��� ���!� 9�:;�� hg�

"#�)%�� �� '�3�6� �#A� ���,��]�zf�{[."5�� �)543 �5�

� '555#A��3 q;3 555X#$%555��� "�� D��555�� ���5556� �555� "#

'#()�)� �!W� 7 D���� �)43 �%�� )E �̀�5�$r� 3��

])@( "�� �� �� �! �� ���+ S ( 3 �)5,]�J��R[."#$%5���

3 ���� �)43 )E W� 7 �� ��A��B� #E� ]�( �� �l

�Y�n)�)�V#.);�X '#�!� D��A$� W� 57 [)B5( �� ##b;

�� 55- �55(� � �� "#$%55��� ��)55E �55��.�55 7 x�55(� 55�

�7�5�)4 �� �5#�3� ��A��B�]a[�%5�� �� D� �5A��B� 3

0();Silha ���Y�!3 ]�O[g�>#X �- '(� ���� 7 �� "#5�

3 "#$%5��� ��)5E W� 57 [)B( "#�)%5�� �5� '5�3�6�

9�:;����)6�� ���� �)43 D��� #E� ��� >#� $ ��5A��B� D3�

�%55�� �55!�55- �55�� �� 55- '55��w"#55� �55� "#$%55��� [)B55(

<E�, l�5:;�� ���5 3 "#�)%5�� �� '�3�6� D�! �)543 �

����55�]��f�p[."#55� �)5543 � 55- <=>55��)8�� �55�

�D �5! �3 57 �� D $>5#� ��5dFl� �� �! �%�� �� �l�:;�

3 ���%55�� |55@$=� D� 55� |55@$=� D�55! W3� �� ���Z$55(�

�,�� �� ��#� ��)� S ( "#$%��� i��( ."5�� C�5! �e5�

F$5:� G�5 �� .� �� "#$%��� �� ( [)B( �(� � �A��B�

1)� '���� ��23 �$���� #� G� �� .� 3+ 9�5:;�� �A��B�

<E�, ��3 "#�)%�� �� '�3�6� D�! ��� '(� ��)�.

ها روش گروه شاهد-الف

T��, �3 7 "�� '#A�4JK�$���� #� G� � . )�O� 5�

3�M��5( "#L��5#� �� � KR/�±�R/RJ3JQBMI ≥(

3 �.���5; �)B� �- ���)� D�� 5.� "#5� �� �5- �)58�� �5�

Check up V5� :; g5, �5�#�E S��� �$(���#� ���5A4� �

�� - ��5��)� v�5=$�� �5,��.D�� 5.� "#5� �� �!�5, �3 57

�- ���, v�=$�� 3 ��$5,��� L��5Y� �5� �@#��5. ':%� ��

3 ��)� T��- '�F( '#A�3 D���#� ��)7 ! �)43 �6��(

"�V� �� <=>� )�'���� �@�4 �� 3 �5#@- "�V5� D��5�#�

D���#� L�� �5! ����#!)� - ���$E� �� 0:; � D�! (#5� "

3 �g�+ 3 ��)� �Z�� �g�+ ]3� �4�� �L$%� �V� V#� T���5r

�lO�$,e7 ��� �����e� h�n� ��� - ��� D3 #X �^�E .

بيماران-ب

��V- � "� 5$7�V� �5- V� :; g, D��#( �$(���#� '����

3 ���55���� �55,�)�+ V55- � "� 55$�g� 33 ����55E �55}���

':�� � '���� ����#� D� � ���X ( D�! ]��5, �56B�� ��

��3�r��), �� v)%�� �)>- v ��QQQQ �)5�d �� Z�

���#�"��5, '5:w "1)5� '5����23 ��5�3 X D���� �6��5(

��$%! .���A; �� .� "�� "#� ��JK'5���� �� F$:� G� � .

1)�2)�M3 � � �O��5( "#L��#� � �Qa/�±OQ/RR3

JQBMI ≥(T���r �A��B� ��� �� �-�]�5( ��13 5,3

W3� �5� ��)5� �$5,e7 �5g�+ '5���� D��5�#� <#=>5; ��

v�=$�� ���( �.���;����� 7 .�� _#$���� �� .� D�� .� "#�

Page 3: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

����� ���� �� �� ���� .��� �������� ��)�� � �(%�

3 ��$5,��� L��5Y� �� �@#��. ':%� �3� �- ���, v�=$��

�̀#��w �� #� "�V� �� <=>� D���#� ��)7 ! �)43 '����

) � )E ��>. � �#@- "�V� D���#� �@�4 ����� D���#� D�5!

�:@�f3 �5�3 d D��5�#� ��5( ���5$E� �5� 0:; 5� D�5!

3 )%5��+ ����5L�3 -+ � ��#5,)- 5#8� ����#!)� - (....

3 �g�+ "#� ��)� �Z�� �g�+ ]3� �4�� �L$%� �V� V#� '5(� .

�$��5�� �� .� �5l T���5r O���e5� h5�n� �� �$5,e7 ��5�

��� D3 #X �^�E �5�� - 3�#5! ��#�)%5�� �5�)7 '5.����

��� ��� -.���>5�)E �5�� ] $�- D� � �$���� �� .� �� Z�

� "#��)Z$� �� 06.z@7 �� 06. Z� "� �3 �#�F- ���� Z�

! �5� ���Z$5(� �5#�F- "5� �5@7 3 "#��)5Z$� D3��� 3�

��� - .D�!��#A� x�(� � D���#� <#=>; ��#A� ADA�

'(� ��)�.

وهاي آنتروپومت تعيين شاخص-پ گيري نمونه ريك

��5=, �5��� '��5�� "$. 57 �� u5X � 5. 5! ��)� ��

�(��3 ���� ��� ��3 �"( D�! #b$� D3�r BMI �- �3� �

55#( )E��>55.� "55(�� �3� 3%3 _#�)$ �̀556#�� _#�)$55(���

��� 7 T#�Y; .���5$#��� D3�� 5; �� ���Z$5(� �5� �� .� �3

)Digital Glass Scale 1)� GES – O7���Y� �+ ('5�� ��

�/Q±�$. 7 ������ _:( x�:� �� 3 iZ- 3�� 3 S 7)@#-

�, .j�( �� �� ���Z$(� �� �� .� ��)D��)��RRRRQ 'E�5(

�3�- '- , ('�� ���/Q±�� � $�#$��( ���$%5�� '#A�3

3 ��)�� ���- �� |$- �- ���r �� iZ- 3�� 0�� 5, �� �!

������ ���)� D��d �, D #7 .�� ��); ������� �3 h#%56;

)S 7)@#- �� ( ��� �3e��)�5� � $� ��(�5�� 7 �:5(��� .

�� 55�- �3� _55���� �� � 55�- '�%55� "� 55; �$#A55�3

������ �� 5� �)5E �5A#:l S���� D�g$�� �� � . �- �, D #7

',�� ."� 5; �$%54 � �� 5.� "(�� �3� D #7 ������ 'g4

�, <=>� + '�%� .3 �- �3� D #7 ������ �� �3� "(

3 1�5�;�� T5��� 5#� D��)5� 5$� _5� �� ���Z$(� �� 3�5�

3 � . �� �� D��>. ��)7 ! T#��; '�� ��� 5$� �$��5(

�5, S����.����5�� �5�! D� 5. D�5BE Ce5r �)58�� �5�

D #7 '. 7 S���� � . _� 0(); �!.

1- American Diabetes Association

#( )E ��>.%D� �)5#4 j�( ��>. �� _#�)$(��� 3 _#�)$

�������$(� � '(�� D3��� �� 3 �$%>� '#A�3 �� �� . u5X

��K�5, D 5#7 ������ 'r $(� �6#�� .Ce5r �)58�� �5�

������ S��; D� . D�BE D #7 )5E ��>5. �5� 9)5� � D�!

3 _,VX _� 0(); ���5�� �@5^�. �5� '5�)� 3� ��JQ

3 �, D #7 ������ �Z#�� 3� �� ��5�+ '(�� ���6� "#L��#�

������ ��� . )E ��>. �)�d �� D #7 ��� 7 W��V7 � .��

��� �� �- �� .� "���2��� �R� �5��)� ��5,�� 'd�( �Q

3 �5, �5$. 7 ��5��3 )5E $#� �@#� �5� S 5( �@5^�.F�

�3� n)#Z� $��(JQQQ i��5��+ �3� �; 3 �, ��4 �6#�� ��

�V� . ��UQf���, ����gL� �� 7 �$��( �4�� .

اندازه گيري فاكتورهاي بيوشيميايي–ت

V#� �$,�� )E V-)@7 �)FBS ( V-)5@7 �5��V�+ W3� ��

���#%-� )�)��;�- ����, )��+ x��X '- , '#-1 500

017 �� g; �3 ���5( 3�� �� 5##b; \� 5� �5� � 5��

3 � ���(2a/�3 �aR�(�, D #7 ������ .�� ( mB(

�� 3 _5#;���V�+ ���5( �5�� W3� �� S ( S�; ]3 $%@-

(� ]3 $%@- �)�r ���#%-� ]3 $%@- � �� $ )'- 5, '#-

�)��;�- ����, )��+ x��X1 500 010�� g; ��5� � 5��

���( 3 �3 ���( 3�� �� ##b; \� � \5#; $� O�/Q

3 �22/��(�, D #7 ������ .D 5; �� ( mB( �� %5#@7

3 _5#;���V�+ ���5( ��� W3� �� ���)�5r ]3 %5#@7

���#%55-� ��Z%55.)+ x��55X '- 55, '55#- ����55, )55��

�)��;�-1 500 032 3�� �� 5##b; \� � �� � ���� g; �

3 ���( 3 � � ���( �\5#; ;OR/�3 �QR/��("#5#A;

�55�� 7 .�$#%55��� �55� "q#;3 X)55*#� ]3 $%55@- �� 55( mB55(

��55�)HDL-C ( 3 �55��V�+ W3� �55� �55#6� v)55(� �� u55X

;3 X)55*#�#"#D3�55r D�55!apo-B �#55(� ])55@�� 055();

$%L�;)Z%. 3 _# h�V5#�� �� @-)'- 5, '5#- �5��'%5�

]�� 5( ����, ��#,D007 49 � 5���� g; �\� 5� �5�

�� $�- ���( 3 �3 ���( 3�� �� ##b;K/R�(����5��

�, D #7 .q;3 X)5*#� ]3 $%5@- �� ( mB(#�$#%5��� �5� "

h-)LDL-C ( �5��3�� . ])� . �� ���Z$(� �� )Friedwald(�

2- LDL-Cholestrol = Total-Cholestrol – (Triglycerid / 5 + DHL-Cholestrol)

Page 4: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

��� 1�2 .� 3�4 :5 2 67 � 8�9:�;� .��< =>< ? @'��... %�

�5- ���! ��)�� D� � 5$�- �5g�+ �� %5#@7 D 5; �V5#� ��

mgRQQ �:(��� �)� ��� 7 . ;��5� �� %#@7 D ; �� ����#�

�� mg/dlRQQ �� ���5, Cer �A��B� .����5�� D� 5� D 5#7

�55@��)Y#@7 "#�)55@7)�!)HbA1c('55#- ��NycoCard

)�)��5;�- ����5, ��n3 ��)>- 'E�(REF-1042184 �5�

�� ##b; \� �)CV ( �� 5$�-K�(�� 5( �$%5; �5-�

�� �%5�� )5E �5@��)Y#@7 "#�)@7)�! D #7 ������ D� �

0#�� In vitro�� ���Z$5(� h��5( �� 5.� 3 ����#� �� ��,��

��� 7 .���5:#- ; T5#� x�5(� 5� W3� "5�� �^FE �)l

'5(� ��5, D��e57 ���X �@��)Y#@7 "#�)@7)�! �� ���3 � .

������ D� � �5@��)Y#@7 "#�)5@7)�! D 5#7 K�� 5$#�3 Y#�

S�; )EEDTA V#�)5�! ])5@�� D3�5r ]�5�3 �5� �� ���

3 ����- v)(� �), �� �.��� ���!� .'#(3 $��� �A� ( �!

V#� 3 ��, "#�)@7)�! S��; �5� \5(�� �! ��)5,.�573o�)-

u#55( i55���+ �55� _55#�3 � �#55(�–"#�)55@7)�! ])55��

�)55, �5� T�55$� �5@��)Y#@7 .9)55@=� �� D���556� u*5(

� i�-�3 �Test Device S�5�; T�d "�� �� � �), �� �.���

��5, ���� �73o�)- "#�)@7)�! ���, \(�� �! "#�)@7)�!

�� ���� $@#. D3� ��>� ���� 3�5���� .�573o�)- �5�)7 5!

)>$%, ])@�� �� �.��� �L�� 3 �$%, $@#. D3� �� ��54

�), ��.������ �� $@#. D3� v)(� �5�+ ��� ��, D #7

))@7)�!��@��)Y#@7 "# (3V� � ���)�; "#�)@7)�!S(��

NycoCard Reader II3 �), �� ����)E "5�� "#5� ':%�

�^�� �� \(��$� ��� 3�HbA1c �)5� �5!�)E ��)�� . 5�

����#� � T^�r �@��)Y#@7 "#�)@7)�! �^�� �V#� x�(�

1)� '���� �� F$:�23� ���5�� v)5E ] 5$�- �� �3 7 ��

)555E )a�<HbA1c (���555A;2K 555Z�)R/U��(3

)5E �5�� �� ] $�- �� �3 7 ��)a�>HbA1c ( ���5A;�Q

Z�)O/2a�(����� 7 h#%6; .

�� 55( mB55("#$%55��� �55� �55(�)���� h�V55�+ W3� �55�

��� '#(�%r 3 �c�3���( 1)� �� 3�$����)'- , '#-

BioVendor '#(�%r �� ����+ �)>- 'E�( ng/ml �/Q

��, 3�)��;�- ��RD191016100 ( �� ���Z$(� ��"#$%���

������$(� �)�d �� ���%�� 3 5� "#;)5#� h$%5#( x�5(�–

�, D #7 ������ "���3+)$X $(�.�� '5#- "�� �� "#$%5���

\#- ;)� ���%5�� �;3 5X # 5��� "#K/�M��)5$���)@#- �5� 3�

D�#$*X �@X #���M2�#(�)�#�+ D��D� ]��;� �#Z�)(��5�

�)55, �55� ���Z$55(� ������$55(� �)55�d .�� W3� "55�� �� 3�

�$�+ D��� �@X ]��)@- ̀����, �� �^��$E� "#$%��� ���%��

�Y� �����>� "#;)#� �� 33 5Y#� D3� ��5, '5#:�; D L��

� '#@X ���Z$5(� �5�� 7 .3 ���5( 3�� �� 5##b; \� 5�

D #7 ������ 'g4 ���( 3 � "#$%��� \5#; ; ��R/J�

3M/O��)�.�� �)54)� S�5; ���)�)! "#$%��� G). '#-

��- �� D #7 ������ �� ��(FX �� S ( 3�#! i�5-�3 �5�)7

�"#55$*� �55� �Al�556$���55� #7 �"#$Y�)55*��+ �"#55$*� TNF-α�

�$� "#$%��� ���>� ])Y�)�)RELM-β(�����. -� �� S��

]�5� � ���56� D� 5� �- '(� "#$%5��� ������$5(� � S 5(

43 �^�E 3 ����� �) �5A#:l ��3��� ���� �>����+ ! ��

"#$%��� �� 7 "##A; .�A#:l ���6� "#�c�! "#$%5��� 5�

3 "( \%r �,�� �� �3�Z$� u�4.D 5#7 ����5�� 'g4

�� ( mB("#$%��� �V5#� �5� �5! �5�)�� S��; J/�k5#��

����� 7 .�� �5(�)���� h�V�+ W3� �� "#�)%�� �� ( mB(

3 �c�3���( 1)� ���5� �$��)'- 5, '5#- Q1- DiaPlus

'#(�%5r �5� ��5Y� �+ �)>5- 'E�5(µIU/ml K/Q3Lot

Number: 24Q1 L6 (�� ���Z$(� �� �)�d �� ���%�� "#�)%��

3 ������$5(� 55� "#;)5#� h$%55#( x�5(�–"���3+)$X $55(�

������ �, D #7.�$�+ 3� �� W3� "�� �� ]�5�)@-)�)� D��5�

5� �5Y� ����%5�� "#�)%�� �� 3 "#;)5#� �5� �����> D 5L��

�����>� 3 h�V�+ �� �̀���, 3 �^��$E� ��5� �5:#- ; T5#� ��

��� 7 ���Z$(� "#�)%�� D� � .���( 3�� �� ##b; \� �

3\5#; ; �5� "#�)%�� D #7 ������ 'g4 ���( 3 �RK/O

3 �RK/O�)� �.

�5� '5�3�6� <E�5,�� "#�)%�� �� '�3�6� �(� � 'g4

"#�)%��HOMA-IR ]2J[3"#�)%�� �� '#(�%r <E�,

QUICKI ]2R[��� 7 ���Z$(� .<E�5,HOMA-IR� 5�

�$5,�� )5E �5�� '58@� v � T^�r x�(�)mmol/l (

�� �$,�� "#�)%�� '8@�)µIU/ml (%6;#'5��w � hK/223

<E�,QUICKI�h$���5L� 1)5��� x)5YA� x�5(� �

�$,�� V-)@73 �$,�� "#�)%�� '8@�.

1- ISHOMA = [FPG (mmol / l x FPI (µIU/ml)] / 22.5 2- (Quantitative Insulin Sensitivity Check Index) = 1 / [log (I0) + log (G0)] ISQUICKi

Page 5: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

����� ���� �� �� ���� .��� �������� ��)�� � �(%#

ها تجزيه-ث وتحليل آماري داده

��)5^ �5� �A��B� "�� �� ��- ���6� S��;Mean ± SD

����� 7 W��V7.���Z$(� �� T^�r D�! ���� D���+ �(� �

����, �=%� ���R��V.� S � SPSS ���, T#@�; 3 ��V�; .

"#L��5#� CF$5E� �)� ��� ��A� �(� � 'g4 D�5! #b$�

��, D #7 ������ �!�, D�! �3 7 �� 33 ��)� _5#YZ; ��

3 � )��+ �� � � tT6$%� ���Z$(� ��� 7 .�5(� � D� 5�

"#� �BE 9�:;�� �� ( [)B( "#L��#� "#$%��� ��"#L��#�

D�55! #b$� ��55, D 55#7 ����55��V#��55�+ W3� �� �L$%55:�!

##b$�3� 3 �)5( #X �L$%5:�! \� 5� ���Z$5(� �5�� 7 .

w� "##A; 'g4 �! <E�, _� $�)X3 $�+ D5, �<E� �5!

"#�)%5�� �5� '5�3�6�3T5��)d [)B55( D3� ���#�#5,)#�

� (�"#$%��� �� V#���+ 3� D�5! ���� T5- �BE )#( 7�

3 �!�, �3 7 ��� 7 ���Z$(� ��)�.�5A��B� "�� ��P 5$�-

��QK/Q��A� ��� 7 �6@; ���.

ها يافته���( "; ���=>��D�! <E�, 3 "#�)%�� �� '�3�6�

T��)d ��#�#,)#���3 57 3� �� ��5, D 5#7 ������ �$��5��

�$���� #�3 ]3�54 �� ���5, �%5��6� �5�� .�5- �)B��5�!

"5( �5� 9)5� � D�5! "#L��5#� �%5��6� '(� <=>� �

�u�554BMI ��3 � �55�� WHR )55E ��>55. � 55�- �3�

3 _#�)$%#( "#�)%����3 ��)� �3 7 3� CF$5E� �!�5,

��A� �5�� �>� D��� �5�!� .])5l "#L��5#� '5���� ��5�

{�/�±ts/�� �)� ]�( �D�)5l + "� 5$�- �5-�3 ]�5(

+ "� $>#��s�)� ]�( .���5A;� �5B#�� T5��)d 8� ��z

3 ����#� �� Z� ���A;{�� Z� �5��)� D��L#( �!�, �� .�.

���A; "#�c�!�3 ����#� �� Z� ��� 5Z� �5� �!�5, �� 5.�

��� - �� C �� TY�� �-��� �V#� .�#� 9)5� � D�! "#L�

]3 $%5@- �V-)5@7 �� ( [)B( �� S�5; ��� %5#@7 D 5; �

HDL-C �LDL-C �HbA1c�"#$%55555��� � "#�)%55555�� �

<E�, "#�)%�� �� '�3�6�HOMA 3<E�, '#(�%5r

"#�)%�� ��QUICKI �� �$���� ���3 �� � �$���� #�3 ��

]3�42�%��6� ��� ��,.���5�� 7 <=>� T^�r j��$�

L��#� �-'8@� "# �� 5( D�5! ]3 $%5@- � S�5; ]3 $%5@-

HDL-C 3<E�, QUICKI �� �� .� 5#� �$��5�� �)5B�

$��5�� �� .� �� $>#� D��� ��A� F��-�'5(�)QK/QP< . (

�$,�� )E ��� '8@� "#L��#�)FBS ( D 5; �� ( mB( �

� �� %555#@7LDL-C ��555^�� �555@��)Y#@7 "#�)555@7)�!

)%HbA1c ( )$(��� )E ��>. �<E�,3 _#�HOMA V#�

$���� �� .� ����!�5, �� .� �� $>#� D��� ��A� F��- �)B�

�)�)QK/QP<(.�� "#$%5��� �� 5( D�5! '58@� "#L��#�

�� .� #� �$����)�!�,( $>#� ���� .� �$����)��)5� (�)5�

�5�A� D��5�+ 8� �� CF$E� "�� ��� ��� �)5:� )��/s±��/p

T55��6� ����/s±�s/�()]3�554�(."#L��55#� "#55�c�!

'558@� �� 55( D�55! "#$%55��� 55! �� �55�� �� �3 557 3�

_#$����)ng/ml MM/s±��/pT5��6� �� p{/s±z�/z(3

�!�5, �3 7)s�/�±�z/tT5��6� �� zp/s±�p/z(5���)5l

�5�A� F��- �� 5� �� $>5#� D��� �)5� )ss�/sP<.( "#5�

�- �3� ��3 � �� �� 9)� � D�! "#L��#�� WHR 3��>5.

3 �� � �� _#�)$(��� )E $��5�� �3 57 3� ! �� ����

�3 73�$���� #� ̀F��- CF$E� �5�A� �)543 D��� '5,��

)ss�/sP<()]3�42(.��V#��5�+ � 3� �L$%5:�!$ 5#b��

'558@� "#L��55#� "#55� D��� �55�A� 3 x)55YA� �L$%55:�!

�� ("#$%��� "#L��#� 3_#�)$5(��� )E ��>. 056. ��

�3 7 #� �$���� ��� 7 ��!�>� )sz/s<P3{t�f/s=r(

)]3�4{.(�L$%:�! "#� "#L��#� "#$%5��� �� ( [)B(

�� ��( <E�, �!D_� $�)X3 $�+ <E�, �'5�3�6� D�5!

"#�)%55�� �55�3T55��)d ���#�#55,)#� ����55�� �� ��55, D 55#7

�� S��Yc#! 3���A� �3 7 ����):�.��V#��5�+ 3� �L$%5:�!

�$#b�� T- D3� �! ���� D�3 57 3� 3 h#6$%5� �L$%5:�!

"#$%��� �� ( '8@� "#L��#� "#� D��� ��A� u�54 �5� ,

"#�)%�� ,�5� ��)5; �����3�3� �5�� 7 ��!�>5� "5(�� .

3 x)YA� �L$%:�! "#�c�! ��A� �5� "#$%5��� "#� D���

_#�)$%#( )E ��>. ,D ; 3 _#�)$(��� ��!�>� �� %#@7

��� 7)]3�4�.(3� �L$%5:�! V#���+ �� <E�5, � 5#b$�

"#�)%�� �� '�3�6�)HOMA ( <E�, �� _� $�)X3 $�+ �!

3T��)d ��, D #7 ������ ���#�#,)#� �3 '5:�� �L$%:�!

"#�)%�� �� '�3�6� <E�, "#� D��� ��A�)HOMA ( �5�

'���� D���#�)ss�/s=P3{�s/s=r(V-)@7 �)ss/s=

P3zt�/s=r(555@7)�! ��555@��)Y#@7 "#�))ssp/s=P

3{��/s=r("#�)%5555555��)sss/s=P3p��/s=r(3

Page 6: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

��� 1�2 .� 3�4 :5 2 67 � 8�9:�;� .��< =>< ? @'��... �-

D ; �� %#@7 )ss�/s=P3{�z/s=r(���3 57 3� T5-

��� 7 ��!�>� .3 �5Z�� 9�5:;�� "#�c�! "#5� D��� �5�A�

"#�)%�� �� '�3�6� <E�,)HOMA ( ]3 $%@- ��HDL

)s{/s=P3�z�/sf=r(�� '#(�%r <E�,3 "#�)%5��

QUICKI)sss/s=P3ts{/sf=r(�3 5557 3� T555-��

�55�� 7 ��!�>55� .�)558�� �55� D�55! <E�55, #w�; "#55#A;

� �Y� $�)X3 $�+T��)d 3 ���#�#,)#� <E�, '�3�6� D�!

3 "#�)%�� �� [)B5( D3� 5� ��5, D 5#7 ����5�� ���5

D3� � 5#b$� �5� �BE )#( 7� V#���+�� "#$%��� �� (

� D�! ���� T-�3 7 3��� 7 ���Z$(� �A��B� ��)�."5�� ��

T��, T6$%� D�! #b$� V#���+)�3� � "( � �� ��); �����

�3� � �- �5� � u�4� "(�� �3� �� �- �3� ':%� � "(��

)E��>55. � �3 �55#(%3 _#�)$ �V-)55@7 � _#�)$55(���

]3 $%5@- � D %#@7 D ; � S�; ]3 $%@-LDL ]3 $%5@- �

HDL �HbA 1c �HOMA-IR 3QUICKI ( �55��)� .��

)E��>5. D�5! #b$� �5- �5�� 7 <=>� V#���+ "�� j��$�

_#�)$55555(���)JUK/Qf=β3QQ�/QP=("#�)%55555�� �

A�B�$.9� �� ���(� �� �� 5��C �;��/� 5 2��D9� .��< EF>< .�G< 8' H IJ0� )��F� (� ��3 ���(��.9� )�2 (

)n=35(گروه مورد)=35n(گروه شاهد متغيرها

�J/M±�R/RJJM/O±OQ/RR†)سال(سن

kg(†�K/�K±KU/MKOJ/�J±MR/M2( وزن

cm(†aJ/�Q±UR/�OJ MK/a±OK/�OR(قدkg/m2(†QU/R±KR/JKM2/J±2J/JR(نمايه توده بدن

cm(†J2/��±RQ/�QM QU/�Q±OK/�QO(اندازه دوركمر cm(†KK/O±22/��U QK/�Q±R2/��J(اندازه دورباسن

Qa/Q±M2/QQU/Q±MJ/Q†نسبت دور كمر به دورباسن

mmHg(†MM/�J±K�/�2R �O/�K±aK/�JQ(فشار خون سيستوليكد ياستوليك mmHg(** 2�/��±�R/UMJ�/�Q±2a/aO(فشار خون

FBS)mg/dl(** a�/��±MU/MQQM/Oa±Oa/�KM

mg/dl(** �a/KK±RQ/2QK UQ/RU±RK/�aQ(كلسترول تام سرم

mg/dl(** �Q/JO±2K/�Oa RR/KK±�M2(تري گليسريد سرم

LDL كلسترول )mg/dl(** R�/K�±OK/JJOa/RK±J�/JR

HDL كلسترول )mg/dl(** OK/U±J�/JaUK/K±J�/JR

OQ/Q±�2/KJ2/2±JK/U **)درصد(هموگلوبين گليكوزيله

ng/ml(†U2/J±�O/UOO/J±RQ/O(رزيستين سرم

µIu/ml(†aJ/�Q±KU/�aRQ/��±UO/�M(انسولين سرم

HOMA-IR(** aJ/2±2K/RaO/K±UO/U(شاخص مقاومت به انسولين

QUICKI(** Q2/Q±J�K/QQ2/Q±2MK/Q(شاخص حساسيت به انسولين

��)� 1)��� �A��B�f'(� ��)� �!�, .* ���6� ± L��>� �SD±Mean ��$%!.†��6� ��)� �3 73 �!�, �3 7 "#� �%��6� �� �PD���+ 8� ��

�):� ��� ��A�)QK/QP>(�** ���6� ��)� �3 73 �!�, �3 7 "#� �%��6� �� P�)���� ��A� D���+ 8� �� )QK/Q<P()��+�� �3 7 3� D�! "#L��#� �%��6� 'g4 t��� 7 ���Z$(� T6$%� .

Page 7: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

����� ���� �� �� ���� .��� �������� ��)�� � �(��

A�B,$� /;�� �� 5��C �;��/� 5 2 ��D9� .��< EF>< 8�K/ �� �:� L� .9� �� �����)��F� ��C (.9� ����3)��C

�2 (

متغيرها گروه مورد گروه شاهد

� �)�O=n(�)�M=n(� �)�M=n(�)�O=n(

s/M±UK/RRM2/a±Ua/R�*†MR/K±J�/RORM/O±KO/R2}†)سال(سن

kg(**KU/�2±MJ/�QK( وزن 22/��±aR/aO†OJ/�2±QK/MO2R/�2±2K/aM

cm(**aO/a±�a/�U2(قد 2M/O±OJ/�KO †JO/K±aR/�UQ RQ/O±J�/�KU

kg/m2(†KU/J±UR/JKKR/R±JU/JK**Ja/J±aJ/J2MU/J±aM/JK(نمايه توده بدن

cm(**RM/�Q±UK/��K(اندازه دوركمر �a/M±QK/�QR **aQ/�Q±R2/�QM 2a/a±JU/�QJ

cm(†RJ/K±UK/��O(اندازه دورباسن RM/U±OJ/��U †�R/a±2�/��2 QO/�2±aU/��R

O�/Q±Ma/QQO/Q±aa/Q**QO/Q±MU/QQU/±MQ/Q* نسبت دور كمر به دورباسن

mmHg(†Qa/�K±KO/�2a(فشار خون سيستوليك JU/�2±�Q/�2� †RQ/�O±Oa/�JJ 2M/�J±KQ/�2U

د ياستوليك �mmHg(**aK/a±2K/aORK/M±�K/UJ**R2/M±QQ/MQa�/M±aU/a(فشار خون

�mg/dl(**2O/�Q±MJ/MR2K/�2±OJ/aU†KU/UU±QQ/�OU QR/KO±QQ/�K( قند خون ناشتا

��mg/dl(†M�/KM±QQ/2(كلسترول تام سرم QK/K2±Oa/2QQ †2J/K2±J�/�UJ UR/R�±MJ/�aa

mg/dl(†2U/J�±J�/�UJ(تري گليسريد سرم QU/RQ±QQ/�OR †UO/KO±Oa/2QO KK/KQ±QQ/�UO

LDL كلسترول )mg/dl(†RK/KJ±Oa/�JM K2/KQ±KU/�2a †aU/KQ±2�/MMRQ/JU±MJ/��a

HDL كلسترول )mg/dl(†K2/a±MJ/JOaK/O±RU/JM†aJ/O±�K/JJM2/J±Oa/JK

KU/Q±2J/KO2/Q±QJ/K†UM/2±KM/UOK/�±QU/U†)درصد(هموگلوبين گليكوزيله

ng/ml(**J�/2±MU/KRQ/R±�K/a**2Q/J±K�/KMa/J±RO/U(رزيستين سرم

µIu/ml(†�a/�J±Q�/2��a/a±K2/�O†UQ/a±M2/RU/�J±�2//2J(انسولين سرم

HOMA-IR(†JQ/J±MO/RJQ/2±OO/J†MM/R±QR/Ua2/O±O2/a(شاخص مقاومت به انسولين

QUICKI(†QJ/Q±JQK/QQ2/Q±J2J/Q†Q2/Q±JQQ/QQJ/Q±2aa/Q(شاخص حساسيت به انسولين

��)� 1)��� �A��B�f'(� ��)� �!�, * ���6� ± L��>� �SD±Mean � ��$%! † ���6� ��� 3 �� � "#� �%��6� ��P�):� ��� ��A� D���+ 8� ��

)QK/QP >(�**� �� ���6� ��� 3 �� � "#� �%��6P�)���� ��A� D���+ 8� �� )QK/Q<P()��+�� �3 7 3� D�! "#L��#� �%��6� 'g4 t��� 7 ���Z$(� T6$%� .

)2MK/Q=β3QQU/QP= ( �3� ����5�� �"5(��)2aQ/Q=β

3Q�/QP= (3"()2�O/Q=β3QRM/QP= (3 T6$%� �)B�

��A� ( ����- "##A; D��� "#$%5��� �� ( [)B �5��)� �5�� �

��555( <E�555, �555! 3 ���#�#555,)#� � _555� $�)X3 $�+ D

<E�, 3 "#�)%�� �� '�3�6� D�! ������ ��� ��5, D #7

��� ����� #w�; "#$%��� �� ( [)B( D3� �$,��.j��$�

)��+�� T^�rt�� 5( [)B5( "#L��5#� �%5��6� '5g4

�� "#$%��� 3��F$:� �� .� �� �3 7 �� 1)5� '5���� �5� 2

�� �$���� �� .� �� "#$%��� �� ( mB( �- ��� 7 <=>�

)5E ��� v)E ] $�- �� �3 7 �� $�- )E ��� �� ] $�-

�,�� ��).2R/2±QJ/K��T��6�QQ/R±MO/O. (��� "��

��A� D���+ 8� �� CF$E� �):� ���.

Page 8: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

��� 1�2 .� 3�4 :5 2 67 � 8�9:�;� .��< =>< ? @'��... �,

A�B�$ � 8�9:�;� .��< �M�3 ���D9� � .K9:@�2 8�F:/� �� �� L� 2 67 N O��9�F��9/P 5 2 67 Q��FR

�� �� 5��C �;��/� .� ��� F�� .9� ����3 ��C � )�2 (.9� �� ��C )��F�(

متغيرها گروه مورد گروه شاهد

rrQaR/Q*QRR/Q*)سال(سن

kg(*2MO/Q*2OM/Q( وزن

cm(*Q�R/Qf*�UK/Q(قد

kg/m2(*�M2/Qf*��M/Qf(بدن نمايه توده

cm(*2�a/*J�J/Q(اندازه دوركمر

cm(*QaK/Q*�MJ/Q(اندازه دورباسن

2UR/Q*J�U/Q* نسبت دور كمر به دورباسن

mmHg(†QOR/Qf*��K/Qf(فشار خون سيستوليك

د ياستوليك mmHg(*�aK/Qf*2UR/Qf(فشار خون

mg/dl(*Ja�/Qf*JQ�/Qf( قند خون ناشتا

mg/dl(*�UO/Qf*�OR/Qf(كلسترول تام سرم

mg/dl(*QQ�/Qf*�2K/Q(تري گليسريد سرم

LDL كلسترول )mg/dl(*�OJ/Qf*2OM/Qf

HDL كلسترول )mg/dl(*Q�Q/Q*�UK/Q

QUa/Q*�QO/Q*)درصد(هموگلوبين گليكوزيله

ng/ml(*�aa/Q*�MM/Qf(رزيستين سرم

Iu/ml(*2/Q*JQ2/Q(انسولين سرم

HOMA-IR(*�O2/0*2�2/0(شاخص مقاومت به انسولين

QUICKI(*�2K/0f*�KU/0f(شاخص حساسيت به انسولين

��� 7 ���Z$(� )( #X �L$%:�! \� � �� ��, D #7 ������ D�! #b$� �� "#$%��� �L$%:�! "##A; 'g4.

*���6�P�):� ��� ��A� D���+ 8� �� )QK/Q>P(†���6� P��A� D���+ 8� �� ��� �)�)QK/Q<P(

���F�/S$��� ��F' �� �/ � 8�9:�;� ? @'�� )BMI (�T >� ��F� ��C ���

�$���� #� �3 7 �$���� �3 7

"#$%���

(ng/

ml)

"#$%���

(ng/

ml)

�� ��); �����(kg/m2)�� ��); �����(kg/m2)

Page 9: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

����� ���� �� �� ���� .��� �������� ��)�� � �(��

A�BU$ 8�F:/� �� �� L� 2 67 N O��9�F��9/P 5 2 67 � 8�9:�;� .��< �M�3 ����D9� � .K9:@�2

�F9V (2 �T >� ��F� ��C � QV�� �� 5��C �;��/� .� ��� F�� 5

r متغيرها

QKO/Q*)سال(سن

2aM/Q† جنس

�QJ/Qf* ديابت

kg(*QaR/Q( وزن

cm(*�OU/Qf(قد

kg/m2(†2Ua/Q(نمايه توده بدن

cm(*�RU/Q(اندازه دوركمر

/cm(†JQU(اندازه دورباسن

QMJ/Qf* نسبت دور كمر به دورباسن

mmHg(†2RO/Qf(فشار خون سيستوليك

mmHg(†JKO/Qf(فشار خون دياستوليك

mg/dl(*�OM/Qf(گلوكز سرم

mg/dl(*QUM/Q(كلسترول تام سرم

mg/dl(†2JM/Qf(تري گليسريد سرم

LDL كلسترول )mg/dl(*��Q/Q

HDL كلسترول mg/dl(*��R/Q

�R�/Qf*)درصد(هموگلوبين گليكوزيله

µIu/ml(†2OJ/Q(نسولين سرما

HOMA-IR(*138/0(شاخص مقاومت به انسولين

QUICKI(*QMU/Qf(شاخص حساسيت به انسولين

.جهت تعيين همبستگي رزيستين با متغيرهاي اندازه گيري شده از ضريب همبستگي پيرسون استفاده گرديد

*���6� P�):� ��� ��A� D���+ 8� �� )QK/Q>P(†���6�P�)���� ��A� D���+ 8� �� )QK/Q<P(

���F�/W$�T >� ��F� ��C� ���:��C 5�' � 8�9:�;� ? @'��

�$���� #� �3 7 �$���� �3 7

"#$%���

(ng/

ml)

"#$%���

(ng/

ml)

(mg/dl)گليسريدتري (mg/dl)گليسريدتري

Page 10: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

��� 1�2 .� 3�4 :5 2 67 � 8�9:�;� .��< =>< ? @'��... �U

���F�/X$�T >� ��F� ��C ��� �� 8�F:/� � 8�9:�;� ? @'��

���F�/Y$ � 8�9:�;� ? @'�� 8�F:/� �� �� L� 67 )HOMA-IR (T >� ��F� ��C����

���F�/Z$8�F:/� �� ��< :[ 67 � 8�9:�;� ? @'�� )QUICKI (�T >� ��F� ��C���

�$���� #� �3 7�$���� �3 7

"#$%���

(ng/

ml)

"#$%���

(ng/

ml)

�$���� #� �3 7�$���� �3 7

"#$%���

(ng/

ml)

"#$%���

(ng/

ml)

�$���� #� �3 7�$���� �3 7

"#$%���

(ng/

ml)

"#$%���

(ng/

ml)

"#�)%��(µIu/ml) "#�)%��(µIu/ml)

�� '�3�6� <E�,"#�)%�� �� '�3�6� <E�,"#�)%��

�� '#(�%r <E�,"#�)%�� �� '#(�%r <E�,"#�)%��

Page 11: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

����� ���� �� �� ���� .��� �������� ��)�� � �(�%

���F�/\$�� ]F7 A�9GV � .9� �� ��C� �� 8�9:�;� .��< EF><

���F�/^$<�T >� ��F� ��C � � /; ������� 8�9:�;� .��< EF>

بحث��A��B� ��( CFE � �@:� [)B5( CF$5E� �-�� 5(

$���� �� .� "#� �� "#$%���� 5#�3 �$��5�� 3 G�5 � 5��

�(� ���)�� ��� ]2K��O�2Q[� ��5- ��5�� "5�� �� �� �A��B

��� "#�3� D� � ��� �� �� 5( [)B5( CF$E� #$%5��� "

1)� '���� �� F$:� G� �� .�233 �$��5�� #� G�5 �� .�

h��( ��3 "( 8� �� D��( �%�! �� uX �5� ��); �����

�(� ���)�� �,�� �� � Z� ���� �.��� �$5,e7 "�� 5�

W��V7 ��( CFE D�! "�� �� �� � ��@d )$� �� �)4)�

3 �� 55� �55A��B� �55(� � �V55�� �)55B� �� �55����)55�� 3

"#5� �5- h#5!� �>5� h#$%��); "#L��5#� �� 5( [)B5(

"#$%555����� 555.� 1)555� '555���� �555� F$555:� G�555 2

)ng/mlO�/Q±RQ/O(3G�55 �� 55.� 3 �$��55�� #� h��555(

)ng/mlO2/Q±�O/U(����5� �)43 D��� ��A� CF$E�.�5��

CF$E� "�� 3 �� � "#� ��� �3 573� ! D��5�+ 58� ��

F��- D��� ��A� � ���,�."#$%��� �� ( [)B( "#�c�!

�� S��Yc#! �� D�! <E�, �5� ��� � "#�)%�� �� '�3�6�

T��)d ���#�#,)#� ��)5�3 �!�, D�! �3 7 �� S��Yc#! ��

:;��9������ .Heilbronn 3���Y�! �>5� �)E �A��B� ��

�- ����� CF$E� �� "#$%5��� �� 5( D�! '8@� "#L��#�

��� �� F$:� G� �� .� 1)� '� 2)ng/ml 2/�±U/J(��� 5.�

3 h��( G� �$��5�� 5#�)ng/ml O/�±2/R( 5#� �� 5.�3

G� )ng/mlU/�±�/R(�5�A� D���+ 8� �� �5�� ��� �5,�� .

�$���� #� �3 7�$���� �3 7

"#$%���

(ng/

ml)

� � � � � �

"#$%���

(ng/

ml)

"#$%���

(ng/

ml)

v)E ] $�- �� �$���� �� .� �$���� �� .��� ] $�- ��

Page 12: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

��� 1�2 .� 3�4 :5 2 67 � 8�9:�;� .��< =>< ? @'��... ��

"�� � �3Fd ��� - '��w ��)5; �5^�� �5� S 5( "#$%5���

�� �� v ����5� �l�5:;�� �5�� �� �� � .�� "#5�c�!

$���� #� G� �� .��3$���� �� �'#(�%5r �5� S ( "#$%�

l�5:;�� "#�)%�� �� �$5,��� ��� 056. 3G�5 5#� �� 5�

3 h#6$%55� �L$%55:�! �55�A� 3 �$55,�� "#�)%55�� "#55� D���

�55�� - ��!�>55� S 55( "#$%55���)QR/Q=P3R2/Q=r(

]2O[.W)� �� �@:� ��A��B� V�)5�; �5- �5���� �>5� �5!

� �� '#(�%r �� ]F$E� \:( "#$%��� �)5, �5� "#�)%5�

]a[.Rajala 3�� D3� D� �5A��B� �� ���Y�! �5! �>5�

����� 5w� "�� �-�� ]F$5E� �� �5,�� ��5g� V-)5@7 �5#�);

�� D�:- "#�)%5�� �5� �5B#�� '#(�%r �; �,�� .�5� !

�! ])@( �� V-)@7 '.���� "#$%���D�� �$@Y5(� �c#!��

�� i!�- �!���)43 "�� ����� T6$%5� w� "�� 5� #%D�!

"#�)%5�� S�#X ]�6$��)��5�!� ]�56$�� ���5���4Rf� V-)5@7

D� $%�)( "��3 #; )#(F��)Z%.�f'#��A. ��3 "#�)%��

)��� T��#;�Z%.])$�� ���#- fJ(�,�� ��]�Q[.

Yaturu 3�� ���Y�! �)E �(� � �5�� - '5��w �5- "#5�

�5� F$5:� G�5 �� 5.� �� "#$%5��� �� ( [)B( "#L��#�

�1)� '��� 233 h��( G� �� .� #�$�������A� CF$E�

D�������55� �)5543 )ng/mlO/2±O/R��T55��6�2/J±M/R.(

5���� �>� "#�c�! �66�� "����� 5( [)B5( "#5� �5-

3 "#$%��� �Z�+ ���!� �3 Y� �)$-�.)TNF-α(D)� 9�:;��

���� �)43 .�)43 "�� �� "#� �5� "#$%5��� �� 5( [)B5(

� <E�, �5� ��)5; �5���� 3 "#�)%5�� �� '�3�6)BMI (

l�:;�� ��� Y� ��!�>� �.������ - '��w '5�3�6� <E�5,

�5� ��)5; ����� �� "#�)%�� ��)BMI ( �3 �� %5#@7 D 5;

]3 $%55@-HDL ���� 9�55:;�� ]2K[.V55#� �55� �55A��B� ��

3 ':�� �L$%:�! �5�A� �5� '5�3�6� <E�5, "#5� D���

"#�)%��)HOMA(�#� �� "#�)5@7)�! �V-)@7 � '���� D��

�55@��)Y#@7�"#�)%55��3D 55; �� %55#@7 ���3 557 3� T55-

��� 7 ��!�>� .3 �5Z�� 9�5:;�� "#�c�! �5�A� "#5� D���

"#�)%�� �� '�3�6� <E�,)HOMA ( ��]3 $%@- HDL

"#�)%�� �� '#(�%r <E�,3QUICKI �3 57 3� T5-��

��� 7 ��!�>�.

Schaffler � �� ���Y�!3 D3� � D� �A��BKKK F$5:� � .

1)� '���� ��232�O$���� #� h��( � . ��5- ����� �>�

"#$%5��� �� 5( [)B( "#L��#� �3 � � u�4 3� ! ��

h��( �� .� ��)ng/ml2/Q±M/U(D��� �5�A� F��5- �)B�

1)5� '5���� �5� F$:� �� .� �� $>#�2)ng/ml �/Q±K/K(

�� #! u�43 "(3 �,�� �� ( [)B( D3� D #w�; ��)Lc

����� "#$%��� .3 "#$%5��� �� 5( [)B5( "#5� "#�c�!

�� ��); �����)BMI ( 3 '5:�� �L$%5:�! h��( �� .� ��

�Z#A� ��� - ��!�>� '���� �� F$:� �� .� �� �Y#;�)^ ��

1)� 2�)43 �l�:;�� "#� ',��� ]2J[.

Yang 5( �5- �5���� �>5� �)E �A��B� �� ���Y�!3 [)B

"#$%��� �� ( 1)� '���� �� F$:� �� .� ��20�� ,�� h!

3 �$, �� h!2�)B� V-)5@7 '5.���� �� u5X 'd�( F��5-

��A� �� ] $�-3 h��( �� .� �� ; "#��X D��� �,��."#5�c�!

V#���+ �� �5� �$,�� "#$%��� [)B( �- ��� - '��w �L$%:�!

�5� ��)5; �5���� � u�4)BMI ( 3 "#5$*� �>5.��)5E

"#�)%55�� �55� '#(�%55r <E�55, �55� �55�� ����55� 9�55:;��

)QUICKI(3 ':�� �)B� 9�:;�� �Z�� �)B� )E V-)@7 ��

����.�� "#$%��� �� ( [)B( �- ��$. 7 ��#$� '��g� ��

1)� '���� �� F$:� �� .�2���� i!�- i��V.� D�4 3 ����

3 ���55 ��55�d 055��� "#$%55��� �� '55������ 55.� ���%55��

��� �,��.3#%��� [)B( ) ��� - �#�"�)5B� ���%��

���� 9�:;�� "#�)%�� �� '#(�%r �� ':���"�� ���� ���Z$5(�

�n�3 �� ""#$%��� ""Y�� T^��� "#�)%�� �� '�3�6� D� �

D�3�r �; '(����)�d �,��]2R[.

Lee ���� �>� �)E �A��B� �� ���Y�!3 ��-"#5� �5g�; ��

� �� ( [)B( 1)5� '���� �� F$:� G� �� .� "#$%��23

$���� #� G� �� .��3]�5� � �3 �� �� .� �5�A� CF$5E�

CF$E� �Y@� ����� �)43 D��� "#$%5��� �� 5( [)B5(

G� ��� "#� 3 #� ��� V5#� G� �5�A� �5�� D��� �5,�� .

"#�c�! ��� - '��w �3�r ��� �� "#$%��� �� ( [)B(

2Q �^��� $>#� �5� �� 5� ��5,��]�a[.j��5$� �� �5Y�

�� "#$%5��� �� 5( [)B( "#L��#� �- ��� �>� �� �A��B�

3� ! 3 �!�, �3 7 ��� �5�A� F��5- �)5B� ��� �� ��)�

D���5A; D�! �$.�� �� V#� �$.�� "�� �,�� �� �� � �� $>#�

�66�� ��]�O ��a�2U[���� ���)5=�! .���5�@d )5$�

W��V7 !�D$������ ��)5� �� [)B5( D3� u�54 #w�5;

"#$%��� �� (�%�� ���� �)543 .S�5d ��5A��B� �5E �

Page 13: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

����� ���� �� �� ���� .��� �������� ��)�� � �(��

CF$5E� 3 �� 5� "#5� �� "#$%55��� �� 5( [)B5( �55��

�� - W��V7 ��� ]2J �2O�2a[3��A��B� L�� #�>�)� $

"#$%��� �� ( [)B( ����W��V57 �� � �� ':%� ���

�� 555- �555�� ]�O ��a�2U[.#555�c�! "Silha3���555Y�!

3 �%5�4 ��5.F$E� #w�; �(� � �� D� �A��B��� ��)5��)!

3 "#$Y�)55*��+ � "#$%55��� �� 55( [)B55( D3� �� "#55$*�

W)� ����� �>� �! ���5 ��54�� i��V5.� h5�� �@d �-

5! �� "5( i��V5.� �5� �� 5�! "#$%��� �� ( [)B( 3�

� u�4 3i!�- ���������� .[)B5(mRNA "#$%5���

��W)� �!D���� 3"#�( S��; �� D #L�> �)B� $>5#�

W)� �� �!D�� � �,��.�! W)� � - �$E�D[)B5( 5�

mRN "�� )*��+"#- ����5(FX [)B5( �5� �5! 3 "#$%5���

��� ##b; D���� �V#� �� �� "#$*� �!��"#$Y�)*��+ �� !

�5� i��V.� D #L�> �V#� �� �5���.W)5� ��5�#; �5� �5!

D� 3��#!3 $()$%; �#� D3� mRNA "�� "#-)5*��+ �5!�

[)B( �� ����(FX 3 "#$%��� "#$Y�)*��+ ;�D #w ��� �����

�55� i��V55.� �� "#55$*� [)B55( �55!�. 55� "$55,�� � u55Yd

���=; �5!mRNA "#$%5��� D��5�� ��#%5� �V5#� �5� ��

3 i��V.� mRNA3 "#$*� �5� i!�5- �� "#$Y�)*��+ �5!� .

"#$*� ����(FX [)B(V#� ���=; "$,�� � �� i��V5.� �5!

�55� �55������;�)55^ �55- [)B55( ����55(FX3 "#$%55���

##b; "#$Y�)*��+ ��� ���-.D�5�� n3 $(� � - "�VL��4

D� [)B55( 3 $()$%55;3��#!mRNA �)55B� �� "#$%55���

�5!� �� i��V.� �� "#$Y�)*��+3 "#$*� 3 i!�- D #L�>

����(FX [)B( D3� ��� "��)*��+"#- �5! ����5� D 5w� 3

�55- �55�$. 7 �55�#$� '55��g���T55��)d 55#� D 55L�� ��

3 $(��F$5E� �� �%5�4 D�!�# "5�� ����5(FX [)B5( C

"#-)*��+ �!��3�3 5� u�4 ���5� �5���� i56� ]2M[.��

�. lNogueias 3��B� �� ���Y�!�A�5- ��� - '��w D�:

�f�#� mRNA �5! �� �5� '5.�� �� "#$%��� D 5�

�� $>#� ��!��� ���� D�5,�� 3B5( m+�5l �)5@� �5�

"� $>#� �5� �)5E �r �5(� 5! �� "5( i��V5.� �5� �5��

�55��� �55� i!�55- u�5543� .2fmB55( 055(); "#$%55���

)��)! ��%�4 D�! )��)! �5!D3 #; ��5# 31)5� �5�eb;

�� ] $�- �),.Jf�#� _#X 05(�3� �� ���4 )��)! "��

�L@��r 3 ��)5� �5! �3� ��D�5� i!�5- �L@��5r 5E+

����.Rf�e� '��3��� ���5#� �� i!�5- \:( mRNA

�! �� �� "#$%���D�), �� �@��r #�3 �@��r ]JQ[.��

�)43 "�� �� "#$%5��� �#� �V#� D3� u�4 #w�; '#�!�

3 �7��)4 �%�� �)5�! '5(� ��5��� ���5� �$E��5,�� ."5��

]��$r� V#� 43� ��.F$E� "�� �- ���� �) ��5.F$E��� �,�

W3� �� CF$E� �� D��o� D�! D #7 ������ �,�� "#$%��� .

"#5� 9�5:;�� D��A$� ��A��B� #E� ]�( �� �l �� !

3 "#$%��� �� ( [)B( ��� �5� '5���� �%5�� �� �� �5!

�� - �(� � �5�� ]2�f2R�2O�J�[."5�� j��5$� #%5Z; �5��

3 D��o� ��.F$E� T#�� �� ��A��B� �� i#X �� 5.� ��#��� ��#

W3� �� ���Z$5(� ��)� C�! D�! <E�, �� �(� � ��)�

'5(� ��)� ����$� 3 TY>� � "#$%��� D #7 ������ D�! .

�)54)� "#$%5��� "#� 9�:;�� �(� � �� D��A$� ��A��B�

3 )E W� 7 �� "#$%5��� [)B5( �- ����� �>� ���

�� i��V.� "�� ��� ���� �� i��V.� G� �� .� ��<E�, D�!

��� 9�:;�� ��� �� "#�)%�� �� '�3�6���]�M�����K[.��

�T��6� Silha 3���Y�!]�O[$%5��� "#5� #3 "HOMA-R

��� - W��V7 �� D��� ��A� 9�:;�� .�5� 5! �� D���5A;

��A��B� i��V.� [)B( �� ( $%��� #':%� �$���� �� .� "

�$���� #� �� .� ������ - W��V7 ���� ��� i��V.� "�� V#� ��

<E�, D�! ��� 9�5:;�� ���54 �� "#�)%�� �� '�3�6� '5,

]2� �2a[.�� �)5543 ]�55�$r� "55�� �55- ��D�55! <E�55,

�� $(�%r "#�)%�� �� '�3�6�������); ��"#$%��� �)B�

��A� D��� 9�:;�� �� �$,����, 3"�� �� �5- ��5�$r� [)B5(

0(); "#$%��� �� ( L�� T��)d hg� 0:; 5� '5���� �5�

#� �����5 �5� V-)@7 �� ( [)B( �"#�)%�� �� '�3�6�

"#55#A;�55� �� 557 �)55�d �55� "#$%55���T55��d �� ��55, $�

'#()*��+ 05��� '5(� "Y�� �- �), �� �$. 7 8� �� �!

3 "#�)%�� �� '�3�6� 1)� '������,�� ]a[."�� 1)5�)�

�̀;�55�d 55� �� ��55A��B� x�55(�55, 0��In vivo D3�

]�� ���!��3 �7��)4 �� �; ��A��B� �� ��)@( ��� D3�

3T3-L1 �7��)4 ��� 7 ��g�>#X. #%Z; �)43 "�� �� "5��

j��$� �$.�� T#�� �� �!�#� D3� �A��B� �� T^�r ����$� D

3TY>� "#$%��� h#8�;���,�� ]a��Q���[.CF5E 5�

]�� D�! ��A��B� �7��)4 D3� �%�� "#��5X [)B5( �5!

�#� mRNA ��� �>� �� "#$%��� �5� ]�2 �J2��K[3"5��

Page 14: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

��� 1�2 .� 3�4 :5 2 67 � 8�9:�;� .��< =>< ? @'��... ��

��A��B���$%��)$� 9�:;�� 3 "#$%��� "#� ����3 �6�3'�

���- '��w �� "#�)%�� ��."����$.� �!�� �>� ��!� i6� �-

3 �Y�n)55�)�V#. �%55�� �� "#$%55��� �Y�n)�)�V#.);�55X �55!

�55,�� �3�55Z$� �7�55�)4 �� + i556� �� '55(� "55Y��.

���-�; �� ]�5�$r� "5�� �- ���5� �5#� �-5��"5�� �5Y� �5-

3 �%�� "#$%��� �7��)4 06.KM�^�� �#5(� mB5(��

��#�+ ��� L��Y� ����� Dn)�)�)! ]J2[3"�� L�� �-��

�%�� �!"#$%��� y��� �#� �� ':%� 0();'#()*��+ �5!�

���d � ;"� "#$%��� �#� T�� '#()�) �!�5� 5,����]�� �

J2[.�3Fd �� "�� � �%5�� �5! D3��5� D3� "#$%5��� n

3�)�3 - ��;)- ����5, S�M)19p13.3 ( ��5�A� D� �5#r��

���� �� � "#�)%�� �� '�3�6� �� ��� �� F$�� ���A$(� �� �-

����� �l�:;�� ��)Lc#! ]JJ[�5B��� �)43 S�d �� )�- �;

��#��5� D�! -��� 3 "#$%��� "#� �5=>� �5(�X '5���� �

'(� ��>� ����.�� ( �! '8@� "#� 9�:;�� �)43 ��)� ��

3 "#$%��� <E�, D�! "#�)%5�� �� '�3�6� V5#� y���5�

���� �)43 �����$�. !'5:�� 9�:;�� ��A��B� �E � ��

"#$%��� "#���5� ��);��5� ]�2 �2U[�5� '5�3�6� 3

"#�)%��]�O[���� �>� �� ���.��� L�� ��A��B� 9�:;�� "#�

3 "#$%��� n �#� �� "#�)%5�� �5� '#(�%5r �� �� �3

� 55Y� ��!�>55����55�]JR[.�55A��B� �� �� 55.� D3� ��V55� D�

3 �$���� ��54�� �5� D�� 5.� �5@�4 �� �$���� #� |5@$=�

�� ��); �����)(BMI '8@� "#� �l�:;�� �5! D����5(FX

3 "#$%��� BMI '���� '#A�3 �� �5�� L� ��!�>� ]JK[.

�� �3Fd �A��B� "�� �� D3� �5! )�� "��#�3��#; �� ����

�! '8@�D5,��� D #w�5; "#$%��� ����(FX '5(� �$.��

�55�#$� �"#$%55��� �55A��3 � 55Y@�d �55� !���%55�� �55!

�� <=>��� �,����)43 "�� �� �� �5�)Lc#! �5A��B� "��

�55�A� 9�55:;�� 3 "#$%55��� �� 55( [)B55( "#55� D���

<E�, �!D� '�3�6� 3 "#�)%�� ��� S��5Yc#! �� ���5

�3 7 �!D3 �!�, �5�� L� ��!�>5� ��)5� �5#A� "�� ��5�� �

'(� �-���d 0��� "#$%��� D� 3 ��� "#� �5� '5�3�6�

�� .��� "#�)%�� ���%���,��.

سپاسگزاري

)5@d ��56#6�; V5- � k5� l �� �5A��B� "�� S���� ���V! S

��g� ����5E3 �Y5,VX S)@d ��L>��� ��eb; ���5��� �$5,

V� :; 3�� ��� ��6#6�; V- � 33 V�� ��L>5��� h%#�)��$�

� 5g; �Y55,VX S)5@d55; �'55(� ��5, "#�.�� �7��%55�)�

�5�� - '- 5, [ 5l "5�� �� �5- D�� .� ����; D��Y�!

�� �o�3 3 �d�5( D�5g� �D 5�! �5�� 5#�� ����+ x�5:d

D 4�g�3 ������� '��g� ��� �� Y>;��.

مĤخذ1. Maggio CA, Pi-Sunyer FX.The prevention and

treatment of obesity: Applicati On to type 2 diabetes. Diabetes Care 1997; 20: 1744-1766.

2. Shimomura I, Funahashi T,Takahashi M,Maeda K, Kotani K,Nakamura T, et al.Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nature Med 1996; 2: 800–802.

3. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377–389.

4. Hotamisligil GS, Spiegelman BM.Tumor necrosis factor : a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271–1278.

5. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763–770.

6. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor- in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409–2415.

7. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor- :direct role in obesity-linked insulin resistance. Science 1993; 259: 87–91.

8. Steppan CM, Balley ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al.The hormone resistin links obesity to diabetes. Nature 2001; 409:307-312.

9. kim KH, Lee K, Moon YS, Sul HS.A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001; 276: 11252-11256.

10. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. The EMBO Journal 2000; 19: 4046–4055.

11. Rajala MW, obici S, Scherer PE, Rosseti L.Adipose derived resistin and gut-derived resistin-like molecule-β selectively impair

Page 15: %%$ˇ#:( ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇijdld.tums.ac.ir/files/site1/user_files_4797e4/eng/tums-A-10-25-292-7361659.pdf · %˛ˆ˙ ˜ ) ˛ˆ˙ ˝ ˘ˇ . 3˜$5,˘ L˙5Y˙ @# . ’:%˘ ˛3

����� ���� �� �� ���� .��� �������� ��)�� � �(�#

insulin action on glucose production. J Clin Invest 2003; 111 :225-230.

12. Banerjiee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Wang J, et al.Regulation of fasted blood glucose by resistin. Science 2004; 303: 1195-1198.

13. Savage ِDB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, considine RV, et al.Resistin /Fizz3 expression in relation to obesity and peroxisome proliferation-activated receptor-γaction in humans. Diabetes 2001; 50: 2199-2202.

14. Nagaev I, Smith U.Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285: 561-564.

15. Engeli JJ, Gozelinak K, Luft FC, Sharma AM.Resistin gene expression in human adipocytes is not related to insulin resistance. Obese Res 2002;10: 1-5.

16. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003; 149: 331-335.

17. Zhang JL, Qin YW, Zheng X, Qiu IJ, Zou DJ.Serum resistin level in essential hypertension patients with different glucose tolerance. Diabet Med 2003; 20 : 828-831.

18. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, et al. Circulatingresistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal,insulin-resistant,and diabetic subjects. J Clin Endocrinol Metabol 2003; 88 : 4848-4856.

19. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, et al.Correlation between serum resistin level and adiposity in obese individuals. Obese Res 2003; 11: 997-1001.

20. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, et al.Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metabol 200; 388: 5452-5455.

21 Youn BS, Yu KU, Park HJ, Lee NS, Min SS, Youn MU, et al.Plasma resistin concentrtions measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metabol 2003; 89 :150-156.

22. McTenan PG, Fisher FM, Valsamakis G,Chetty R,Harte A, Calaire L, et al.Resistin and type 2 diabetes:regulation of resistin expression by insulin and resiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metabol 2003; 88: 6098-6106.

23. Schaffler A, Buchler C, Muller ladner U , Herfarth H, Ehling A, Paul G, et al

.Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus. Horm Metab Res 2004; 36: 702-7.

24. Yang J, Li M, Wu CY, Wang H, Xu Qs, Deng JY.Reduced resistin levels in patients with type 2 diabetes mellitus.Zhonghua Yi Xue Za Zhi 2003 ;83 (17) :1471-4.

25. Yaturu S, Daberry RP, Rains J, Jain S.Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. Cytokine 2006; 34: 219-223.

26. Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, et al.Relationship between Serum Resistin Concentrations and Insulin Resistance in Nonobese, Obese, and Obese Diabetic Subjects. J Clin Endocrinol Metabol 2004; 89: 1844 – 1848.

27. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003; 88: 1730-1736.

28. Hasegawa G, Ohata M, Ichida Y, Obayashi H, Shigeta M,Yamasaki M, et al.increased serum resistin levels in patients with type2 diabetes are not linked with markers of insulin resistance and obesity. Acta Diabetol 2005; 42 :104-109.

29. Gui Y, Silha JV.and Murphy LJ. Sexual dimorphism and regulation of resistin, adiponectin, and leptin expression in the mouse. Obesity Research 2004; 12:1481-1491.

30. Nogueiras R, Gualillo O, Caminos JE, Casanueva FF, Diegues C.Regulation of resistin by gonadal,thyroid hormone, and nutritional status.Obes Res 2003; 11 :408-414.

31. Shuldier A, Yang R, Gong D.Resistin, obesity, and insulin resistance the emerging role of the adipocyte as an endocrine organ. N Engl J Med 2001; 345; 1345-1346.

32. Juan CC, Au LC, Fang VS, Kang SF, Ko YH, Kuo SF, et al. Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids. Biochem Biophys Res Commun 2001; 289: 1328-1333.

33. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001; 98:502–506.

34. Janke J, Engeli S, Gorzelniak K, Luft F, Sharma A. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002; 10: 1–5.

35. Fehmann HC, Heyn J. Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls. Horm Metab Res 2002; 34: 671-673.